- Atomico has led a $16M seed round in Frontier Health, supporting JUNO, an AI tool designed for NHS administrative teams rather than clinicians. This area has been mostly overlooked by health AI investors until now.
- When JUNO was first used at East Sussex Healthcare NHS Trust, it saved 221 staff days in eight weeks and reduced the median patient pathway time by 22%. This gave Atomico rare, concrete evidence at the seed stage.
- This funding comes at a time when seven million patients are on the NHS waiting list. Administrative failures, not just clinical capacity, are now seen as a major cause of these delays.
In the NHS AI market, many startups have raised money to build tools for clinicians and clinical documentation, but very little investment has gone to the administrative teams who manage patient flow and coordinate care. Atomico sees this as an opportunity to address an overlooked area.
Today, Frontier Health announced a $16M seed round led by Atomico, with firstminute capital and XYZ Venture Capital also joining. The company makes JUNO, an AI tool designed for NHS administrative teams rather than clinicians. This is Frontier Health’s first institutional funding.
“Most enterprise AI is still looking for proof that it works in the real world. Frontier Health already has it – inside one of the most complex and demanding environments on the planet,” says Atomico partner Andreas Helbig, who led the deal.
Why this Atomico bet is different
Atomico manages $4.7B across its funds and is known for supporting early- and growth-stage European companies such as Klarna, Supercell, DeepL, and Hinge Health.
While Atomico does lead some seed rounds, such as Wonder Studios at $12M in October 2025 and deeploi at $6.5M in early 2024, it is usually selective and looks for strong founders and solid proof of concept. The $16M round for Frontier Health is larger than both of these previous examples.
Before founding Frontier Health in 2024, Rachel Finegold, who is the solo founder, spent 6 years as the healthcare lead at Palantir Technologies, working with over 40 NHS hospitals. This gave her a deep understanding of the system’s constraints before starting development, which is rare among health AI founders.
Finegold is not the first founder to move from Palantir’s NHS work to a venture-backed company. Other former Palantir engineers have raised $12M to modernise legacy ERP systems, and another team has landed $12M to build an AI operating system for pharma. What sets Finegold apart is her six years of work directly within NHS hospitals, rather than just advising from the outside.
At East Sussex Healthcare NHS Trust, JUNO was used in a real-world setting and delivered results that Atomico checked independently. In eight weeks, it saved 221 staff days on repetitive tasks and cut the median patient pathway time by 22%, the company claims.
Getting this kind of traction at the seed stage in the NHS is rare. Most health AI pilots last for months and do not produce clear results. East Sussex delivered measurable outcomes investors could trust.
Frontier Health’s market focus and how it differs from competitors
Right now, most NHS AI efforts focus on ambient scribing, which means tools that transcribe clinical conversations and create medical notes. Tandem Health, which recently teamed up with Accurx to bring AI-assisted clinical documentation to 98% of UK GPs, raised $50M in a Series A round in June 2025, bringing its total funding to over $59M.
TORTUS, backed by Khosla Ventures and used in nine NHS sites in a 17,000-patient trial, has raised about $8.5M. Accurx, Heidi, and Microsoft Dragon Copilot are also active in this busy, clinician-focused market.
Frontier Health does things differently. JUNO is designed for administrative coordinators who follow up on test results, identify patients stuck in care pathways, and flag risks before they cause delays or missed targets.
This group has largely been ignored by health AI investors, even though it has a significant impact on patient flow. Some NHS-focused founders are starting to notice this gap, but none have focused on administrative coordinators until now.
The need for better operations is obvious. Seven million patients are on the NHS waiting list, and almost 100,000 have been waiting for over a year. Many of these delays are due to administrative problems such as missed follow-ups, unaddressed results, and issues not escalated quickly enough. In 2024, administrative AI got 60% of all healthcare AI investment, but most of that money went to clinical documentation, not to the staff who manage patient flow.
What the funding signals
The global market for AI agents in healthcare is worth $1.11B in 2025 and is expected to reach $6.92B by 2030, with a 44.1% annual growth rate. The new funding will help JUNO expand to more NHS Trusts, improve its technology, and grow the team. All $16M raised comes from this round.
“The team’s depth of NHS experience and proven execution make them uniquely placed to lead this category,” says firstminute capital partner Lina Wenner.
XYZ Venture Capital founder and managing partner Ross Fubini added, “There is no one more familiar with the data, the tech, the ground truth inside health systems.”
This deal brings up a bigger question for the European healthtech market. If administrative failures are as much to blame for NHS waiting lists as clinical capacity, why has so little investment gone into this area?
Frontier Health’s early results show the problem can be solved, but few people with the right access have tried. Atomico’s $16M seed investment suggests they see this category as bigger than most people think.
